Novavax Inc. execs tried to shift the focus to promising secondary and exploratory endpoint data showing efficacy of its Resvax respiratory syncytial virus (RSV) vaccine on the severe impacts of RSV infection, but Wall Street refused to be diverted Thursday, sending company shares (NASDAQ:NVAX) to a 52-week low on news of the primary endpoint miss in the phase III Prepare maternal immunization study.